Fierce Pharma Asia—Takeda’s cell, gene therapy deals; BMS-BeiGene Abraxane brawl
Takeda is investing more in cell and gene therapy through new deals with Poseida Therapeutics and Immusoft targeting liver and neurometabolic disorders, respectively. BeiGene’s Abraxane China licensing deal with Bristol Myers Squibb’s Celgene is falling apart amid manufacturing problems and a legal battle. And more. 1. Billions club: Takeda taps Poseida for 2nd $ 1B-plus gene… Read More »
